Rapid Transformation of Myelodysplastic Neoplasm to Myelodysplasia-related Acute Myeloid Leukemia with Central Nervous System Leukemia in a Young Adult
- 1Department of General Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, Maharashtra, India
Abstract
Myelodysplastic neoplasms (MDSs) are clonal hematopoietic stem cell disorders that progress to acute myeloid leukemia (AML) in 25%–30% of patients, typically over many years. Rapid transformation and central nervous system (CNS) involvement at AML diagnosis are uncommon in adults and confer a poor prognosis. We report a 35-year-old man with MDS who progressed to AML within 8 months and presented with extreme hyperleukocytosis, pulmonary infiltrates, leukemic retinopathy, and acute neuropsychiatric symptoms. Flow cytometry demonstrated nonmonocytic AML with aberrant CD7 expression and co-expression of CD34 and CD123. Next-generation sequencing revealed RUNX1 and ZRSR2 mutations defining AML with myelodysplasia-related features, with DNMT3A and TET2 mutations indicating evolution from an antecedent clone. Brain magnetic resonance imaging showed diffuse pachymeningeal enhancement, and cerebrospinal fluid confirmed CNS leukemia. Despite standard induction and intrathecal chemotherapy, bone marrow assessment demonstrated primary refractory disease. This case highlights aggressive secondary AML with adverse biology, CNS involvement, and induction failure.
Related
- ACUTE PROMYELOCYTIC LEUKEMIA FOLLOWING MYELODYSPLASTIC NEOPLASM IN AN OCTOGENARIAN PATIENT: A CASE REPORT
- Acquired Elliptocytosis With Hemolytic Anemia in Myelodysplastic Neoplasm With del(20q)
- Case Report: Durable response to lenalidomide rechallenge after azacitidine failure in myelodysplastic neoplasm with del(5q)
- UM171-Expanded Cord Blood Transplantation in Adults with High- and Very High-Risk Acute Leukemia and Myelodysplastic Syndrome: Combined Results of Two Prospective Phase II Trials
- Pancreatic solid papillary neoplasm with high-grade malignant transformation and multiple hepatic metastases in an elderly male: a case report
BibTeX
@article{mahashabde2026rapid,
title = {{Rapid Transformation of Myelodysplastic Neoplasm to Myelodysplasia-related Acute Myeloid Leukemia with Central Nervous System Leukemia in a Young Adult}},
author = {Madhulika L. Mahashabde and Sai Karthik Guniganti and Gaurav A. Chaudhary and Sharveen Kumbhar},
journal = {Annals of African Medicine},
year = {2026},
month = jun,
doi = {10.4103/aam.aam_143_26},
url = {https://doi.org/10.4103/aam.aam_143_26},
note = {CC BY-NC-SA 4.0},
}
RIS
TY - JOUR
TI - Rapid Transformation of Myelodysplastic Neoplasm to Myelodysplasia-related Acute Myeloid Leukemia with Central Nervous System Leukemia in a Young Adult
AU - Madhulika L. Mahashabde
AU - Sai Karthik Guniganti
AU - Gaurav A. Chaudhary
AU - Sharveen Kumbhar
PY - 2026
DA - 2026/06/05
JO - Annals of African Medicine
DO - 10.4103/aam.aam_143_26
UR - https://doi.org/10.4103/aam.aam_143_26
AB - Myelodysplastic neoplasms (MDSs) are clonal hematopoietic stem cell disorders that progress to acute myeloid leukemia (AML) in 25%–30% of patients, typically over many years. Rapid transformation and central nervous system (CNS) involvement at AML diagnosis are uncommon in adults and confer a poor prognosis. We report a 35-year-old man with MDS who progressed to AML within 8 months and presented with extreme hyperleukocytosis, pulmonary infiltrates, leukemic retinopathy, and acute neuropsychiatric symptoms. Flow cytometry demonstrated nonmonocytic AML with aberrant CD7 expression and co-expression of CD34 and CD123. Next-generation sequencing revealed RUNX1 and ZRSR2 mutations defining AML with myelodysplasia-related features, with DNMT3A and TET2 mutations indicating evolution from an antecedent clone. Brain magnetic resonance imaging showed diffuse pachymeningeal enhancement, and cerebrospinal fluid confirmed CNS leukemia. Despite standard induction and intrathecal chemotherapy, bone marrow assessment demonstrated primary refractory disease. This case highlights aggressive secondary AML with adverse biology, CNS involvement, and induction failure.
SN - 1596-3519
SN - 0975-5764
ER -